China IVD Raw Materials Market Size, Share & Trends Analysis Report By Product Type (Antibody, Antigens, Proteins, Enzymes, Biological Buffers, Substrates, Others), By Technology (Molecular Diagnostics, Clinical Chemistry, Immunochemistry, Others), By End User (Diagnostic Laboratories, Pharmaceutical & Biotechnological Companies, Others) and Forecasts, 2025-2033

China IVD Raw Materials Market Size

The China IVD raw materials market size was valued at USD 1,787.5 million in 2024 and is projected to reach from USD 2,024.0 million in 2025 to USD 4,381.2 million by 2033, growing at a CAGR of 15.0% during the forecast period (2025–2033). Factors such as the growing prevalence of chronic diseases, advancements in diagnostic technologies, and increased investment in healthcare infrastructure propel market growth. In particular, China’s strong focus on improving healthcare accessibility and the surge in demand for personalized diagnostics is driving the adoption of advanced in-vitro diagnostic (IVD) materials across the country.

China IVD Raw Materials Market Growth Factors

Rising incidence of chronic diseases and the aging population

China’s growing burden of chronic diseases, such as diabetes, cardiovascular conditions, and cancer, is a significant factor driving the IVD raw materials market. According to the Chinese Diabetes Society, over 116 million people in China were diagnosed with diabetes in 2024, and the number is expected to increase significantly by 2030. The aging population is another contributing factor, with over 19% of China’s population aged 65 or older by 2024. These demographic shifts are creating an increasing demand for diagnostic testing to manage chronic diseases and monitor health in the aging population, thus driving the need for innovative and reliable IVD raw materials.

Restraining Factors

Regulatory complexities and approval delays

The regulatory landscape in China poses challenges to the growth of the IVD raw materials market. The China National Medical Products Administration (NMPA) has implemented stringent regulations for medical devices, including IVD products, which increases the complexity and time required for product approvals. Changes to regulatory policies, such as revising China’s Medical Device Supervision and Administration Regulation in 2021, have resulted in additional compliance burdens for local and international manufacturers. These stringent requirements slow down the commercialization of new products and make market entry more difficult, impacting the growth rate of the IVD raw materials market.

Market Opportunity

Advancements in personalized medicine and molecular diagnostics

China is witnessing a rapid shift toward personalized medicine, driven by advancements in molecular diagnostics, which presents a substantial opportunity for the IVD raw materials market. The Chinese government’s initiatives, such as the Healthy China 2030 plan, aim to modernize the healthcare system and enhance disease prevention through advanced diagnostics. This has led to a surge in demand for raw materials required for genetic testing, cancer diagnostics, and infectious disease screening. Partnerships between Chinese biotech companies and global diagnostic firms are also fostering the development of customized diagnostic solutions, providing significant opportunities for growth in the IVD raw materials sector.

Regional Insights

The market is characterized by diverse growth patterns across China’s major cities, driven by healthcare infrastructure, population demographics, and economic development. As the largest market in the Asia-Pacific region, China benefits from advancements in precision medicine and biopharmaceuticals. The growing aging population and increasing prevalence of chronic diseases further drive demand for diagnostic tests and IVD products.

• Beijing leads China's IVD raw materials market due to its advanced healthcare infrastructure and significant government investment in medical research. As the capital, Beijing is home to several major diagnostic companies and research institutions, contributing to the rapid adoption of molecular diagnostics and immunoassays. The city accounted for over 20% of China’s IVD market in 2024.
• Shanghai is another key player in the IVD raw materials market, benefiting from its position as a hub for pharmaceutical companies and biotech startups. The city’s focus on healthcare innovation and partnerships with international companies has led to the rapid growth of personalized medicine and molecular diagnostics. Shanghai’s healthcare expenditure reached USD 64 billion in 2024, supporting the expansion of diagnostic capabilities.
• Guangzhou is experiencing substantial growth in the IVD raw materials market, driven by its expanding healthcare sector and government initiatives to promote healthcare modernization. The city focuses on improving diagnostic facilities, particularly infectious disease testing, and chronic disease management. Guangzhou’s IVD market grew by 10.5% in 2024, making it one of the fastest-growing regions.
• Shenzhen is emerging as a biotech hub in China, with increasing investments in healthcare technology and innovation. The city’s proximity to Hong Kong has facilitated collaborations with international companies, boosting the development of advanced diagnostic tools. Shenzhen’s IVD market is characterized by a strong focus on molecular diagnostics and immunochemistry, growing at 11.3% annually.
• Chengdu is witnessing growth in its IVD raw materials market due to the rising prevalence of chronic diseases and the expansion of healthcare services in southwestern China. The city’s government has invested heavily in healthcare infrastructure, mainly in rural areas, driving demand for diagnostic tools and raw materials. The market in Chengdu is expected to grow at a CAGR of 10.9%.
• Wuhan is crucial in China’s IVD raw materials market, especially in developing infectious disease diagnostics. After the COVID-19 pandemic, the city has become a focal point for diagnostic research and development. Wuhan’s IVD market is characterized by strong government support and collaborations with international diagnostic companies, growing at a rate of 11.5% annually.

China IVD Raw Materials Market Segmentation Analysis

By product type

Antibody dominates the product type segment and is expected to grow at a CAGR of 14.3% over the forecast period. Antibodies represent the leading product type in China’s IVD raw materials market, driven by the increasing use of immunoassays for disease diagnosis. Monoclonal and polyclonal antibodies are in high demand for cancer diagnostics, particularly for lung cancer, which is prevalent in China.

By technology

Immunochemistry dominates the technology segment and is expected to grow at a CAGR of 14.8% over the forecast period. The growing focus on early disease detection and the development of genetic tests for cancer and rare diseases is fueling this growth. PCR and next-generation sequencing (NGS) technologies are leading molecular diagnostics.

By end-user

Pharmaceutical and biotechnological companies dominate the end-user segment and is expected to grow at a CAGR of 15.4% over the forecast period. Pharmaceutical and biotechnological companies are China's most prominent end-users of IVD raw materials. These companies increasingly utilize raw materials for drug development, clinical trials, and companion diagnostics, which is expected to drive the market's growth.

Analyst Perspective

As per our analyst, the market is poised for rapid expansion in the coming years. This growth is primarily driven by advancements in diagnostic technologies, increasing healthcare investments, and a rising demand for personalized medicine in China. The country's healthcare reforms, aimed at improving disease prevention and early detection, also play a significant role in market evolution. Additionally, China’s collaboration with international diagnostic firms facilitates the development of innovative solutions, particularly in molecular diagnostics and immunoassays, making it a key market for global and local players.